Market closed
Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
$MRK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
74,000
ISIN
US58933Y1055
Website
Merck & Co. Metrics
BasicAdvanced
$202B
11.69
$6.88
0.44
$3.16
4.03%
Price and volume
Market cap
$202B
Beta
0.44
52-week high
$134.63
52-week low
$75.82
Average daily volume
17M
Dividend rate
$3.16
Financial strength
Current ratio
1.41
Quick ratio
0.827
Long term debt to equity
69.182
Total debt to equity
71.992
Dividend payout ratio (TTM)
45.54%
Interest coverage (TTM)
19.22%
Management effectiveness
Return on assets (TTM)
13.81%
Return on equity (TTM)
39.29%
Valuation
Price to earnings (TTM)
11.693
Price to revenue (TTM)
3.182
Price to book
4.19
Price to tangible book (TTM)
18.58
Price to free cash flow (TTM)
11.94
Dividend yield (TTM)
3.93%
Forward dividend yield
4.03%
Growth
Revenue change (TTM)
4.10%
Earnings per share change (TTM)
667.14%
3-year revenue growth (CAGR)
5.80%
3-year earnings per share growth (CAGR)
7.18%
3-year dividend per share growth (CAGR)
5.73%
What the Analysts think about Merck & Co.
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merck & Co. Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merck & Co. News
AllArticlesVideos
Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
Business Wire·1 day ago
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
CNBC Television·2 days ago
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Seeking Alpha·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $202B as of May 14, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 11.69 as of May 14, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of May 14, 2025, the dividend rate is $3.16 and the yield is 4.03%. Merck & Co. has a payout ratio of 45.54% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.